Introduction
============

Age-related macular degeneration (AMD) is the most common cause of irreversible central vision loss worldwide \[[@r1]\]. It can be divided into early and advanced (late) forms. Early AMD is characterized by the presence of drusen or pigmentary abnormalities in the retinal pigment epithelium (RPE), while advanced AMD includes two clinical types---geographic atrophy of the RPE (dry AMD) and choroidal neovascularization (wet AMD). Age-related macular degeneration is a complex disease caused by the combination of genetic predisposition and environmental factors \[[@r2]-[@r4]\]. The inheritance of AMD is polygenic and multifactorial: race, age, smoking, body mass, and body mass index have all been associated with AMD \[[@r2],[@r5]-[@r9]\]. In the past five years, significant progress has been made in our understanding of AMD genetics through studies that identified specific single nucleotide polymorphisms (SNPs) significantly associated with AMD. The discovery of the strongest associations of AMD with the variants of complement factor H (*CFH*; OMIM [134370](http://www.ncbi.nlm.nih.gov/omim/134370)) \[[@r10]-[@r13]\] and *ARMS2/HTRA1* (age-related maculopathy susceptibility 2, OMIM [611313](http://www.ncbi.nlm.nih.gov/omim/611313); the high temperature requirement factor A1, OMIM: [602194](http://www.ncbi.nlm.nih.gov/omim/602194)) \[[@r14]-[@r17]\] has led to new hypotheses regarding the pathogenesis of this disease. *CFH* is primarily associated with the formation of drusen that often characterizes both types of advanced AMD in Caucasian populations, whereas *ARMS2/HTRA1* is mainly associated with wet AMD \[[@r18]\]. Other than these two major loci, three other members of the complement system, complement component 2 (*C2*; OMIM [217000](http://www.ncbi.nlm.nih.gov/omim/217000)), complement component 3 (*C3*; OMIM [120700](http://www.ncbi.nlm.nih.gov/omim/120700)), and complement factor B (*CFB*; OMIM [138470](http://www.ncbi.nlm.nih.gov/omim/138470)), were also found to be associated with AMD \[[@r10],[@r19]-[@r21]\]. Most of these genes are complement pathway-associated genes, with the products participating in the alternative complement pathway and playing important roles in the complement system. Many studies have provided evidence that the complement system is involved in the pathogenesis of AMD and may have a pivotal effect on the formation and development of the disease \[[@r13],[@r22]-[@r24]\]. However, the specific role of the complement system in the etiology of AMD is difficult to elucidate, and questions remain as to whether other components from this system are associated with AMD.

Complement factor D (CFD) is a protein of the trypsin family encoded by the *CFD* [gene](http://en.wikipedia.org/wiki/Gene) (OMIM [134350](http://www.ncbi.nlm.nih.gov/omim/134350)) and is involved in the [alternative complement pathway](http://en.wikipedia.org/wiki/Alternative_complement_pathway) of the [complement system](http://en.wikipedia.org/wiki/Complement_system) \[[@r25],[@r26]\]. CFD is unique among serine proteases in that it requires neither enzymatic cleavage for expression of proteolytic activity nor inactivation by a serpin for its control \[[@r27]\]. It is best known for its role in humoral suppression of infectious agents and has a high level of expression in fat, suggesting a role for adipose tissue in immune system biology ([CFD](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=629http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=1675)). In this study, we investigated the association of *CFD* with advanced AMD in a Caucasian population.

Methods
=======

Subjects and clinical diagnosis
-------------------------------

This study was approved by the Institutional Review Board of the University of California, San Diego. Informed consent was signed by all subjects before participation in the study. One hundred and seventy-eight nonfamilial advanced AMD patients and 161 age-matched normal controls (60 years or older with no drusen or RPE changes) as well as an independent replication cohort with 445 nonfamilial advanced AMD patients and 190 age-matched normal controls were recruited using the standard ophthalmic examination protocol. Grading was performed using a standard grid classification suggested by the International Age-related Maculopathy (ARM) Epidemiological Study Group for the age-related maculopathy and age-related macular degeneration group \[[@r28]\]. All the participants were Caucasian.

Genotyping
----------

Six SNPs, [rs1683564](http://www.ncbi.nlm.nih.gov/snp?term=rs1683564), [rs35186399](http://www.ncbi.nlm.nih.gov/snp?term=rs35186399), [rs1683563](http://www.ncbi.nlm.nih.gov/snp?term=rs1683563), [rs3826945](http://www.ncbi.nlm.nih.gov/snp?term=rs3826945), [rs34337649](http://www.ncbi.nlm.nih.gov/snp?term=rs34337649), and [rs1651896](http://www.ncbi.nlm.nih.gov/snp?term=rs1651896) at the *CFD* locus were chosen, which were either tag SNPs or those that might affect the function of *CFD* ([Figure 1](#f1){ref-type="fig"}). A Caucasian cohort of 178 advanced AMD patients was genotyped and allele frequencies were compared with 161 age- and ethnicity-matched normal controls by laboratory personnel blinded to the case/control status. Potential positive findings were tested for replication in an independent cohort of 445 advanced AMD patients and 190 normal controls.

![Six single nucleotide polymorphisms (SNPs) on complement factor D (*CFD).* Shown is the corresponding location of each SNP on *CFD* (chromosome:19; location:19p13.3) that was chosen in this study.](mv-v16-2273-f1){#f1}

Genotypes of six SNPs were achieved by primer extension of multiplex PCR products followed with a SNaPshot using an ABI 3100 genetic analyzer (Applied Biosystems, Foster City, CA).

Statistical analysis
--------------------

Deviation from Hardy--Weinberg equilibrium was assessed, with a statistical significance level of 0.01. A chi-square test was performed to assess evidence for association. The statistical significance level was adjusted by Bonferroni correction. Linkage disequilibrium (LD) patterns and haplotype blocks were defined using Haploview 4.1.

Results
=======

We genotyped six SNPs that tag the majority of *CFD* haplotypes and investigated allelic association with AMD. Four SNPs, [rs1683564](http://www.ncbi.nlm.nih.gov/snp?term=rs1683564), [rs35186399](http://www.ncbi.nlm.nih.gov/snp?term=rs35186399), [rs1683563](http://www.ncbi.nlm.nih.gov/snp?term=rs1683563), and [rs3826945](http://www.ncbi.nlm.nih.gov/snp?term=rs3826945), located either at the promoter region, exon, or intron of *CFD*, exhibited no association with advanced AMD in our study population. The SNP [rs34337649](http://www.ncbi.nlm.nih.gov/snp?term=rs34337649), in exon 5 of *CFD*, showed no polymorphisms in our data ([Table 1](#t1){ref-type="table"}).

###### Association between 5 single nucleotide polymorphisms (SNPs) on complement factor D (*CFD)* and advanced age related macular degeneration (AMD)

  **SNP**                                                         **Minor allele**   **Frequency in case**   **HWE in case**   **Frequency in control**   **HWE in control**   **Frequency in HapMap**   **p (allelic)**
  --------------------------------------------------------------- ------------------ ----------------------- ----------------- -------------------------- -------------------- ------------------------- -----------------
  [rs1683564](http://www.ncbi.nlm.nih.gov/snp?term=rs1683564)     G                  0.424                   8.96E-01          0.409                      1.57E-01             0.460 (CEPH)              0.710
  [rs35186399](http://www.ncbi.nlm.nih.gov/snp?term=rs35186399)   A                  0.006                   9.97E-01          0.003                      9.99E-01             N.A.                      0.658
  [rs1683563](http://www.ncbi.nlm.nih.gov/snp?term=rs1683563)     G                  0.371                   3.47E-01          0.414                      8.21E-01             0.353                     0.253
  [rs3826945](http://www.ncbi.nlm.nih.gov/snp?term=rs3826945)     G                  0.346                   9.18E-01          0.309                      9.68E-01             0.351                     0.318
  [rs34337649](http://www.ncbi.nlm.nih.gov/snp?term=rs34337649)   T                  0                       N.A.              0                          N.A.                 N.A.                      N.A.

Shown are minor alleles for each SNP on *CFD*; frequencies for our advanced AMD, control groups and HapMap European groups; Hardy--Weinberg equilibrium (HWE) test; and P(allelic) values. (The P(allelic) value cannot be calculated when there is a count equal to zero.)

Of the six SNPs, [rs1651896](http://www.ncbi.nlm.nih.gov/snp?term=rs1651896), which is located at the 3′ region of *CFD*, was found to be marginally associated with advanced AMD (P(allelic)=0.07, risk allele A: 37.4% in cases versus 30.7% in controls) in a Caucasian cohort of 178 advanced AMD cases and 161 normal controls. The result was further investigated in an independent replication cohort of 445 advanced AMD patients and 190 controls. No further significant association was observed for either the replication cohort (P(allelic)=0.882, risk allele A: 37.2% in cases versus 37.6% in controls) or the combined cohort (P(allelic)=0.223, risk allele A: 37.2% in cases versus 34.5% in controls, [Table 2](#t2){ref-type="table"}).

###### Association between complement factor D (*CFD)* single nucleotide polymorphism (SNP) [rs1651896](http://www.ncbi.nlm.nih.gov/snp?term=rs1651896) and advanced age related macular degeneration (AMD) in the discovery, replication and combination cohorts

  **Cohort**    **Phenotype**   **N**   **MAF (A)**   **HWE**    **p (allelic)**
  ------------- --------------- ------- ------------- ---------- -----------------
  Discovery     Advanced AMD    178     0.374         4.21E-01   0.07
  Cohort        Control         161     0.307         9.97E-01    
  Replication   Advanced AMD    445     0.372         9.52E-01   0.882
  Cohort        Control         190     0.376         8.41E-01    
  Combination   Advanced AMD    623     0.372         9.05E-01   0.223
  Cohort        Control         351     0.345         9.21E-01    
  HapMap-CEU    Control         112     0.321                     

Shown are the corresponding numbers of the *CFD* SNP [rs1651896](http://www.ncbi.nlm.nih.gov/snp?term=rs1651896) for both advanced AMD and control groups in the discovery cohort, replication cohort, and combination cohort. Frequencies for the minor allele in our cohorts and HapMap European group, hardy Weinberg equation (HWE) test, and P(allelic) values are given.

Linkage disequilibrium patterns and haplotype blocks were defined by combining the six SNPs ([Figure 2](#f2){ref-type="fig"}). No significant association was found between the haplotypes and AMD phenotypes. The SNP [rs34337649](http://www.ncbi.nlm.nih.gov/snp?term=rs34337649) was not shown in the plot because it was not a detected polymorphism in our data set.

![Linkage disequilibrium (LD) plot of six single nucleotide polymorphisms (SNPs) on complement factor D (*CFD).* The physical position of each SNP is shown above the plot. Darker shades of red indicate higher values of the LD coefficient (D\'). The numbers in pink and white squares show the % of D\' between SNPs with incomplete LD. Blue squares with no number indicate a pairwise linkage disequilibrium of 1 between SNPs, supported by logarithm (base 10) of odds (lod) scores \< 2.](mv-v16-2273-f2){#f2}

Discussion
==========

The [alternative complement pathway](http://en.wikipedia.org/wiki/Alternate_complement_pathway) is one of three distinct complement pathways and is important in the clearance and recognition of pathogens in the absence of antibodies \[[@r29]\] ([Figure 3](#f3){ref-type="fig"}). It is triggered by spontaneous C3 hydrolysis to form C3a and C3b, which makes C3b capable of binding to a pathogenic membrane surface. After binding with an activator membrane, C3b is bound by [CFB](http://en.wikipedia.org/wiki/Complement_factor_B) to form C3bB. Complement factor H acts as one of the primary regulators by inhibiting the binding of CFB to C3b and also by degrading C3b. In the presence of [CFD](http://en.wikipedia.org/wiki/Factor_D), C3bB is cleaved into C3bBa and C3bBb (C3 convertase). After hydrolysis of C3, C3 convertase and C3b become C3bBbC3b, which cleaves C5 into C5a and C5b. A membrane attack complex (MAC) is formed through subsequent reactions, which inserts into the cell membrane and initiates cell lysis \[[@r18],[@r30],[@r31]\]. In this pathway, CFB and CFD are involved in the activation and amplification loop, whereas CFH is a fluid phase inhibitor. To keep the complement activity under control, the competition between CFH and CFB binding to C3b on the host or pathogen cells needs to be tightly regulated. How this control is achieved is not completely clear \[[@r18]\].

![The alternative complement pathway. The principal components of the alternative complement pathway from C3 to the stage of membrane attack complex (MAC) formation are shown in detail. Complement factor H (CFH) with the dotted arrow acts as an inhibiting regulator while Complement factor B (CFB) and Complement factor D (CFD) with the filled arrows are activators.](mv-v16-2273-f3){#f3}

Compared with other complement factors, CFH, C3, and CFB have been associated with AMD in many independent studies. However, the exact role they play in the pathogenesis of AMD and whether their effects are mediated through the complement system or through another pathway is poorly understood. Previously, CFD was studied using a *CFD* ^−/−^ mouse model, with the conclusion that eliminating the alternative pathway was neuroprotective and reduced photoreceptor susceptibility to light-induced damage \[[@r25]\]. Contrary to this finding, no significant association between *CFD* SNPs and advanced AMD was found in this study. Due to the dearth of information about the relationship between *CFD* and AMD, further research in other populations may be warranted. Our results suggest it is unlikely that *CFD* is a major functional candidate gene conferring risk for AMD. However, due to the relatively small sample size, this study has limited power to detect minor effects. Extended cohorts will be needed to confirm the genetic role of *CFD*. Future research should also focus on a comprehensive understanding of genetic variants throughout all pathways of the complement system. By identifying high risk variants and improving our understanding of the complement system, early intervention for patients at risk of developing AMD and novel gene-based treatments may become a reality.
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